GenAllertOB: Fear Conditioning Paradigm in Obesity

Sponsor
Istituto Auxologico Italiano (Other)
Overall Status
Completed
CT.gov ID
NCT05768659
Collaborator
(none)
48
1
4.4
10.8

Study Details

Study Description

Brief Summary

Fear processing in obesity and specifically the ability to i) learn and remember threatening stimuli, and ii) implicitly (i.e., unconsciously) and explicitly (consciously) discriminate them from neutral ones, will be investigated in affected individuals through the fear-conditioning paradigm.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Fear Conditioning

Study Design

Study Type:
Observational
Actual Enrollment :
48 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Implicit Reactions to Threats in Individuals With Obesity: Primary Evidence From Fear Conditioning Paradigm
Actual Study Start Date :
Jun 7, 2022
Actual Primary Completion Date :
Oct 20, 2022
Actual Study Completion Date :
Oct 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Cases

Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).

Behavioral: Fear Conditioning
It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested. Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered.

Controls

Not-hospitalized participants with a healthy weight

Behavioral: Fear Conditioning
It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested. Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered.

Outcome Measures

Primary Outcome Measures

  1. SCRs) [Baseline]

    The event-related skin conductance responses (SCRs) in the case of the CS will be measured. This will represent the implicit index.

Secondary Outcome Measures

  1. Recognition % [baseline]

    Level of accuracy (in %) in recognizing and discriminating the CS from NS will be computed. This will represent the explicit index.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Right-handed

  • diagnosis of obesity (the level of body mass index - BMI - higher or equal to 30).

Exclusion criteria:

• concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Istituto Auxologico Italiano - Ospedale San Giuseppe Piancavallo VCO Italy 28824

Sponsors and Collaborators

  • Istituto Auxologico Italiano

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Istituto Auxologico Italiano
ClinicalTrials.gov Identifier:
NCT05768659
Other Study ID Numbers:
  • 21X101
First Posted:
Mar 14, 2023
Last Update Posted:
Mar 14, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Istituto Auxologico Italiano
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 14, 2023